Birdwatch Note
2023-11-25 17:51:55 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
ファンタローは白血病の生存者で、8歳と13歳で2回診断された 白血病から脳への転移の可能性が高く、データが得られている 白血病細胞がこれまで知られていなかった経路で脳に転移することが、マウスの研究で明らかになったことを報告する論文が、今週掲載される。この新知見は、急速な転移を特徴とする白血病の新たな治療機会を示している可能性がある。 https://www.natureasia.com/ja-jp/research/highlight/12603 急性リンパ性白血病 (ALL) 治療終了1年後に脳腫瘍を発症した8歳男児例を経験した.患児は4歳時にALLを発症, 約3年間の化学療法終了後, 完全寛解を維持していたが, 治療終了約1年後に脳腫瘍が発見された。 https://www.jstage.jst.go.jp/article/jjph1987/7/6/7_6_615/_article/-char/ja/
Written by AD9CAAF21CCDDCEEC318C6E5A38BFAEC037E7CE458F714F2ADDB11236A564695
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1728399174167830882
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1728471592358093088
- noteId - 1728471592358093088
- participantId -
- noteAuthorParticipantId - AD9CAAF21CCDDCEEC318C6E5A38BFAEC037E7CE458F714F2ADDB11236A564695 Participant Details
- createdAtMillis - 1700934715724
- tweetId - 1728399174167830882
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 1
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- ファンタローは白血病の生存者で、8歳と13歳で2回診断された 白血病から脳への転移の可能性が高く、データが得られている 白血病細胞がこれまで知られていなかった経路で脳に転移することが、マウスの研究で明らかになったことを報告する論文が、今週掲載される。この新知見は、急速な転移を特徴とする白血病の新たな治療機会を示している可能性がある。 https://www.natureasia.com/ja-jp/research/highlight/12603 急性リンパ性白血病 (ALL) 治療終了1年後に脳腫瘍を発症した8歳男児例を経験した.患児は4歳時にALLを発症, 約3年間の化学療法終了後, 完全寛解を維持していたが, 治療終了約1年後に脳腫瘍が発見された。 https://www.jstage.jst.go.jp/article/jjph1987/7/6/7_6_615/_article/-char/ja/
Note Status History
createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
2023-11-25 17:51:55 UTC (1700934715724) |
1969-12-31 23:59:59 UTC (-1) |
2023-11-26 03:30:36 UTC (1700969436505) |
NEEDS_MORE_RATINGS | 1969-12-31 23:59:59 UTC (-1) |
Note Ratings
rated at | rated by | |
2023-11-25 17:58:30 -0600 | Rating Details | |
2023-11-25 17:36:19 -0600 | Rating Details | |
2023-11-25 16:57:12 -0600 | Rating Details | |
2023-11-25 16:33:36 -0600 | Rating Details | |
2023-11-25 16:28:28 -0600 | Rating Details | |
2023-11-25 16:03:00 -0600 | Rating Details | |
2023-11-25 15:43:20 -0600 | Rating Details | |
2023-11-25 15:32:41 -0600 | Rating Details | |
2023-11-25 15:24:21 -0600 | Rating Details | |
2023-11-25 15:17:34 -0600 | Rating Details | |
2023-11-25 14:12:29 -0600 | Rating Details | |
2023-11-25 14:07:53 -0600 | Rating Details | |
2023-11-25 12:56:48 -0600 | Rating Details | |
2023-11-25 11:56:43 -0600 | Rating Details | |
2023-11-26 06:09:03 -0600 | Rating Details | |
2023-11-26 05:52:10 -0600 | Rating Details | |
2023-11-26 05:22:30 -0600 | Rating Details | |
2023-11-26 04:25:23 -0600 | Rating Details | |
2023-11-26 04:22:02 -0600 | Rating Details | |
2023-11-26 04:11:52 -0600 | Rating Details | |
2023-11-26 02:43:17 -0600 | Rating Details | |
2023-11-26 02:35:34 -0600 | Rating Details | |
2023-11-26 01:42:24 -0600 | Rating Details | |
2023-11-26 00:19:28 -0600 | Rating Details | |
2023-11-25 23:32:18 -0600 | Rating Details | |
2023-11-25 21:27:00 -0600 | Rating Details | |
2023-11-25 21:09:44 -0600 | Rating Details | |
2023-11-25 20:10:20 -0600 | Rating Details | |
2023-11-25 20:01:37 -0600 | Rating Details | |
2023-11-25 19:51:54 -0600 | Rating Details | |
2023-11-25 19:12:59 -0600 | Rating Details | |
2023-11-25 18:41:06 -0600 | Rating Details | |
2023-11-27 18:08:52 -0600 | Rating Details | |
2023-11-27 17:58:41 -0600 | Rating Details | |
2023-11-27 18:07:38 -0600 | Rating Details | |
2023-11-27 18:02:38 -0600 | Rating Details | |
2023-11-26 22:26:16 -0600 | Rating Details | |
2023-11-26 04:15:37 -0600 | Rating Details | |
2023-11-26 03:57:16 -0600 | Rating Details | |
2023-11-26 03:29:15 -0600 | Rating Details | |
2023-11-26 03:21:29 -0600 | Rating Details | |
2023-11-26 03:14:54 -0600 | Rating Details | |
2023-11-26 03:08:03 -0600 | Rating Details | |
2023-11-26 02:47:40 -0600 | Rating Details | |
2023-11-26 02:44:41 -0600 | Rating Details | |
2023-11-26 02:10:23 -0600 | Rating Details | |
2023-11-26 01:21:04 -0600 | Rating Details | |
2023-11-26 00:09:20 -0600 | Rating Details | |
2023-11-25 23:57:31 -0600 | Rating Details | |
2023-11-25 23:21:29 -0600 | Rating Details | |
2023-11-25 22:48:47 -0600 | Rating Details | |
2023-11-25 22:39:45 -0600 | Rating Details | |
2023-11-25 22:36:42 -0600 | Rating Details | |
2023-11-25 21:48:14 -0600 | Rating Details | |
2023-11-25 20:47:30 -0600 | Rating Details | |
2023-11-25 19:34:43 -0600 | Rating Details | |
2023-11-25 19:06:06 -0600 | Rating Details | |
2023-11-25 19:01:18 -0600 | Rating Details | |
2023-11-25 18:00:27 -0600 | Rating Details | |
2023-11-25 17:43:49 -0600 | Rating Details | |
2023-11-25 17:42:05 -0600 | Rating Details | |
2023-11-25 17:32:14 -0600 | Rating Details | |
2023-11-25 17:30:32 -0600 | Rating Details | |
2023-11-25 16:57:27 -0600 | Rating Details | |
2023-11-25 16:43:44 -0600 | Rating Details | |
2023-11-25 16:43:05 -0600 | Rating Details | |
2023-11-25 16:36:23 -0600 | Rating Details | |
2023-11-25 16:25:13 -0600 | Rating Details | |
2023-11-25 16:19:39 -0600 | Rating Details | |
2023-11-25 16:02:16 -0600 | Rating Details | |
2023-11-25 16:02:13 -0600 | Rating Details | |
2023-11-25 15:33:25 -0600 | Rating Details | |
2023-11-25 15:16:01 -0600 | Rating Details | |
2023-11-25 15:15:35 -0600 | Rating Details | |
2023-11-25 15:13:08 -0600 | Rating Details | |
2023-11-25 15:11:12 -0600 | Rating Details | |
2023-11-25 14:22:54 -0600 | Rating Details | |
2023-11-25 13:50:34 -0600 | Rating Details | |
2023-11-25 12:29:12 -0600 | Rating Details | |
2023-11-25 12:14:56 -0600 | Rating Details | |
2023-11-25 12:03:41 -0600 | Rating Details | |
2023-11-26 04:58:05 -0600 | Rating Details | |
2023-11-25 19:44:40 -0600 | Rating Details | |
2023-11-25 16:54:57 -0600 | Rating Details | |
2023-11-25 16:29:03 -0600 | Rating Details |